Publication NumberUS 20160208011
Assignees
  • The Board of Trustees of the Leland Stanford Junior University
  • The United States Government as represented by the Department of Veterans Affairs
StatusPatent Application
Application Number14/991813
AvailabilityUnknown
Filing Date2016-01-08
Publication Date2016-07-21

Abstract

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

Claims

  • 1. A method of treating an adult mammal for an aging-associated impairment, the method comprising: modulating CCR3 in the mammal in a manner sufficient to treat the adult mammal for the aging-associated impairment.
  • 2. The method according to claim 1, wherein modulating CCR3 comprising modulating eotaxin-1/CCR3 interaction.
  • 3. The method according to claim 2, wherein eotaxin-1/CCR3 interaction is modulated by reducing active systemic eotaxin-1 in the mammal.
  • 4. The method according to claim 3, wherein the active systemic eotaxin-1 is reduced in the mammal by administering to the mammal an effective amount of an active systemic eotaxin-1 reducing agent.
  • 5. The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent is an eotaxin-1 binding agent.
  • 6. The method according to claim 5, wherein the eotaxin-1 binding agent comprises an antibody or binding fragment thereof.
  • 7. The method according to claim 5, wherein the eotaxin-1 binding agent comprises a small molecule.
  • 8. The method according to claim 4, wherein the active systemic eotaxin-1 reducing agent comprises an eotaxin-1 expression inhibitory agent.
  • 9. The method according to claim 8, wherein the eotaxin-1 expression inhibitory agent comprises a nucleic acid.
  • 10. The method according to claim 1, wherein eotaxin-1/CCR3 interaction is modulated by reducing CCR3 activity in the mammal.
  • 11. The method according to claim 10, wherein the CCR3 activity is reduced in the mammal by administering to the mammal an effective amount of an active CCR3 reducing agent.
  • 12. The method according to claim 11, wherein the active CCR3 reducing agent is a CCR3 binding agent.
  • 13. The method according to claim 12, wherein the CCR3 binding agent comprises an antibody or binding fragment thereof.
  • 14. The method according to claim 12, wherein the CCR3 binding agent comprises a small molecule.
  • 15. The method according to claim 11, wherein the active CCR3 reducing agent comprises a CCR3 expression inhibitory agent.
  • 16. The method according to claim 15, wherein the CCR3 expression inhibitory agent comprises a nucleic acid.
  • 17. The method according to claim 1, wherein the mammal is a primate.
  • 18. The method according to claim 17, wherein the primate is a human.
  • 19. The method according to claim 1, wherein the adult mammal is an elderly mammal.
  • 20. The method according to claim 19, wherein the elderly mammal is a human that is 60 years or older.
  • 21. The method according to claim 1, wherein the aging-associated impairment comprises a cognitive impairment.
  • 22. The method according to claim 1, wherein the adult mammal suffers from an aging associated disease condition.
  • 23. The method according to claim 1, wherein the aging associated disease condition is a cognitive decline disease condition.

Related Grants

10 related grants.

Sign in to view

Related Publications

33 related publications.

Sign in to view

Covalent Data is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.

Create a Free account today to see all results.
Get all Pro account features for 14 days.

Join today for free

No credit card required